These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33825507)

  • 61. Entering the era of highly effective modulator therapies.
    Dave K; Dobra R; Scott S; Saunders C; Matthews J; Simmonds NJ; Davies JC
    Pediatr Pulmonol; 2021 Feb; 56 Suppl 1():S79-S89. PubMed ID: 33434412
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators.
    Rehman T; Karp PH; Tan P; Goodell BJ; Pezzulo AA; Thurman AL; Thornell IM; Durfey SL; Duffey ME; Stoltz DA; McKone EF; Singh PK; Welsh MJ
    J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34166230
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation.
    Caverly LJ; Riquelme SA; Hisert KB
    Clin Chest Med; 2022 Dec; 43(4):647-665. PubMed ID: 36344072
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.
    Davies JC; Wainwright CE; Canny GJ; Chilvers MA; Howenstine MS; Munck A; Mainz JG; Rodriguez S; Li H; Yen K; Ordoñez CL; Ahrens R;
    Am J Respir Crit Care Med; 2013 Jun; 187(11):1219-25. PubMed ID: 23590265
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations.
    Guimbellot J; Solomon GM; Baines A; Heltshe SL; VanDalfsen J; Joseloff E; Sagel SD; Rowe SM;
    J Cyst Fibros; 2019 Jan; 18(1):102-109. PubMed ID: 29685811
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor.
    Borowitz D; Lubarsky B; Wilschanski M; Munck A; Gelfond D; Bodewes F; Schwarzenberg SJ
    Dig Dis Sci; 2016 Jan; 61(1):198-207. PubMed ID: 26250833
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.
    Brewington JJ; McPhail GL; Clancy JP
    Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections.
    Durfey SL; Pipavath S; Li A; Vo AT; Ratjen A; Carter S; Morgan SJ; Radey MC; Grogan B; Salipante SJ; Welsh MJ; Stoltz DA; Goss CH; McKone EF; Singh PK
    mBio; 2021 Dec; 12(6):e0314821. PubMed ID: 34903059
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Whole-blood transcriptomic responses to lumacaftor/ivacaftor therapy in cystic fibrosis.
    Kopp BT; Fitch J; Jaramillo L; Shrestha CL; Robledo-Avila F; Zhang S; Palacios S; Woodley F; Hayes D; Partida-Sanchez S; Ramilo O; White P; Mejias A
    J Cyst Fibros; 2020 Mar; 19(2):245-254. PubMed ID: 31474496
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation].
    Gomez-Pastrana D; Nwokoro C; McLean M; Brown S; Christiansen N; Pao CS
    An Pediatr (Engl Ed); 2019 Mar; 90(3):148-156. PubMed ID: 30093322
    [TBL] [Abstract][Full Text] [Related]  

  • 71. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Modulator Combination Improves In Vitro the Microrheological Properties of the Airway Surface Liquid of Cystic Fibrosis Airway Epithelia.
    Ludovico A; Moran O; Baroni D
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232697
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.
    Flume PA; Liou TG; Borowitz DS; Li H; Yen K; Ordoñez CL; Geller DE;
    Chest; 2012 Sep; 142(3):718-724. PubMed ID: 22383668
    [TBL] [Abstract][Full Text] [Related]  

  • 74. IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation.
    van de Peppel IP; Doktorova M; Berkers G; de Jonge HR; Houwen RHJ; Verkade HJ; Jonker JW; Bodewes FAJA
    J Cyst Fibros; 2019 Mar; 18(2):286-293. PubMed ID: 30279125
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype.
    Clancy JP; Johnson SG; Yee SW; McDonagh EM; Caudle KE; Klein TE; Cannavo M; Giacomini KM;
    Clin Pharmacol Ther; 2014 Jun; 95(6):592-7. PubMed ID: 24598717
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis.
    Guerra L; Favia M; Di Gioia S; Laselva O; Bisogno A; Casavola V; Colombo C; Conese M
    Expert Opin Drug Discov; 2020 Aug; 15(8):873-891. PubMed ID: 32290721
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation.
    Trimble AT; Donaldson SH
    J Cyst Fibros; 2018 Mar; 17(2):e13-e16. PubMed ID: 29079142
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa.
    Barnaby R; Koeppen K; Nymon A; Hampton TH; Berwin B; Ashare A; Stanton BA
    Am J Physiol Lung Cell Mol Physiol; 2018 Mar; 314(3):L432-L438. PubMed ID: 29146575
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Extended-culture and culture-independent molecular analysis of the airway microbiota in cystic fibrosis following CFTR modulation with ivacaftor.
    Einarsson GG; Ronan NJ; Mooney D; McGettigan C; Mullane D; NiChroinin M; Shanahan F; Murphy DM; McCarthy M; McCarthy Y; Eustace JA; Gilpin DF; Elborn JS; Plant BJ; Tunney MM
    J Cyst Fibros; 2021 Sep; 20(5):747-753. PubMed ID: 33549519
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Ivacaftor for patients with cystic fibrosis.
    Wainwright CE
    Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.